TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03750448

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised rehabilitation
Description: The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
Study: NCT02553863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture for 30min \[twice weekly for 8 weeks\]

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard care
Description: Standard care
Study: NCT04119154

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast Microhalography (CEM)
Description: Fine needle aspirates evaluated by CEM device
Study: NCT01110655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous hypertonic Saline
Description: Intravenous 100mL bolus of 3% saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hypertonic saline
Description: Oral 100mL bolus of 3% saline
Study: NCT00439465

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Ex-vivo expanded effector cells
Description: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
Study: NCT03504930

Intervention type: OTHER
Intervention: Impact of biotherapy on postoperative morbidity in ulcerative colitis
Description: Impact of biotherapy on postoperative morbidity, quality of life, sexual function, sexual health in ulcerative colitis
Study: NCT02037152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body scan exercise
Description: The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. The audio content is adapted from the body scan exercises traditionally taught in evidence-based mindfulness interventions.
Study: NCT03737994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO
Study: NCT03816163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Administered as an intravenous infusion.
Study: NCT00176865

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: 15 mg/kg IV or orally bid and discontinued on Day +45 unless GVHD is present

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: 15 mg/kg IV or orally bid and discontinued on Day +45 unless GVHD is present

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Description: 500 mg/kg IV weekly beginning on Day +7 until Day +100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Description: 500 mg/kg IV weekly beginning on Day +7 until Day +100

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Description: 500 mg/kg IV weekly beginning on Day +7 until Day +100
Study: NCT03816163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: Administered as an intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Administered as an intravenous infusion
Study: NCT03366883

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin Plus 5-FU (TCF)
Description: preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy
Description: preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week)
Study: NCT00534911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Participants will receive 12 weeks of CBT designed for youth with IBD. During sessions, participants will learn new ways of thinking (e.g., reconstruction of personal physical illness narratives, coping strategies, social skills) and behaving (e.g., positive activities, family communication, sleep hygiene, relaxation) to improve emotional and physical outcomes. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.~Other Name: Primary and secondary coping enhancement training (PASCET)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Non-directive Therapy (SNDT)
Description: SNDT is a 12-week non-directive therapeutic intervention. Participants will receive social support and quality information about the warning signs and risk factors for depression. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.
Study: NCT03187561

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Infant sleep-adapted coparenting intervention
Description: The Family Foundations intervention, as originally formulated, and a sleep-adapted Family Foundations intervention, will be implemented to participants in arm 1 and arm 2, respectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant sleep-adapted coparenting intervention
Description: The Family Foundations intervention, as originally formulated, and a sleep-adapted Family Foundations intervention, will be implemented to participants in arm 1 and arm 2, respectively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant sleep-adapted coparenting intervention
Description: The Family Foundations intervention, as originally formulated, and a sleep-adapted Family Foundations intervention, will be implemented to participants in arm 1 and arm 2, respectively.
Study: NCT02426385

Intervention type: DEVICE
Intervention: FineVision Toric
Description: Posterior chamber IOL which consists in a small plastic lens with plastic side struts, called haptics, to hold the lens in place within the capsular bag inside the eye
Study: NCT01092455

Intervention type: DRUG
Intervention: Heparin N reduction
Description: Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.
Study: NCT03867760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recorded Hypnosis Intervention
Description: The RHI consists of four digital recordings developed by the investigator using standardized hypnosis scripts for pain reduction and uploaded to a MP3 player. The scripts were developed for patients with chronic pain and tested by a psychologist who is an expert in hypnosis research. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days). The script includes an induction, suggestions for how to access inner resources and manage pain, and post-hypnotic suggestions for permanence of hypnosis benefits and self-hypnosis practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recorded Relaxation Intervention
Description: The recorded relaxation intervention consists of four digital recordings developed by the investigator using standardized relaxation scripts and uploaded to a MP3 player. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days).
Study: NCT01717352

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep and Eating Routine
Study: NCT02589067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
Study: NCT01426854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac Ophthalmic Suspension, 0.1%
Description: Topical ocular administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac Vehicle Ophthalmic Solution
Description: Inactive ingredients used as placebo; topical ocular administration
Study: NCT01261949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined frontal and temporal rTMS
Description: Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 1000 stimuli of 1Hz rTMS over the right DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporal low frequency rTMS
Description: Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold)
Study: NCT02955901

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 day low residue diet prior to the colonoscopy
Description: 3 day low residue diet prior to the colonoscopy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 1 day low residue diet prior to the colonoscopy
Description: 3 day low residue diet prior to the colonoscopy
Study: NCT00493805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of pegylated interferon alfa-2b and ribavirin
Description: 1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks(Group A) or 60 weeks (Group B) postrandomization.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks (Group A) or 60 weeks (Group B) postrandomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of pegylated interferon alfa-2b and ribavirin
Description: 1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks
Study: NCT00604162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam COLON
Description: The PillCam COLON capsule is an ingestible capsule equipped with an endoscope that has two imagers, enabling it to acquire video images from both ends. the device measures 31 by 11 mm and acquires images at a rate of 4 frames per second. Recording and downloading of data are similar those of the data for small-bowel capsule endoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard colonoscopy
Description: Standard colonoscopy was the standard against which capsule endoscopy was compared,and it was performed after capsule endoscopy (after capsule excretion or at least 10 hours after capsule ingestion, whichever came first), on either the same day as ingestion or the next morning.
Study: NCT04032418

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03303781

Intervention type: OTHER
Intervention: Cardiac Rehabilitation
Description: phase II center-based cardiac rehabilitation

Intervention type: OTHER
Intervention: Cardiac Rehabilitation
Description: phase II center-based cardiac rehabilitation
Study: NCT03721718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5300
Description: \[Part A\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) \[Part B\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) GLS-5300 0.6 mg at 0, 4, and 12 weeks (N=25) GLS-5300 0.6 mg at 0 and 8 weeks (N=25)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5300
Description: \[Part A\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) \[Part B\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) GLS-5300 0.6 mg at 0, 4, and 12 weeks (N=25) GLS-5300 0.6 mg at 0 and 8 weeks (N=25)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5300
Description: \[Part A\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) \[Part B\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) GLS-5300 0.6 mg at 0, 4, and 12 weeks (N=25) GLS-5300 0.6 mg at 0 and 8 weeks (N=25)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5300
Description: \[Part A\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) \[Part B\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) GLS-5300 0.6 mg at 0, 4, and 12 weeks (N=25) GLS-5300 0.6 mg at 0 and 8 weeks (N=25)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellectra 2000 Electroporation
Description: GLS-5300 administered ID followed by Cellectra 2000 Electroporation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellectra 2000 Electroporation
Description: GLS-5300 administered ID followed by Cellectra 2000 Electroporation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellectra 2000 Electroporation
Description: GLS-5300 administered ID followed by Cellectra 2000 Electroporation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellectra 2000 Electroporation
Description: GLS-5300 administered ID followed by Cellectra 2000 Electroporation
Study: NCT05406050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference eldecalcitol soft capsule
Description: 0.75 μg, produced by Chugai Pharmaceutical Co., Ltd. Japan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference eldecalcitol soft capsule
Description: 0.75 μg, produced by Chugai Pharmaceutical Co., Ltd. Japan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test eldecalcitol soft capsule
Description: 0.75 μg, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test eldecalcitol soft capsule
Description: 0.75 μg, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China
Study: NCT02273492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asasantin ER

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized breakfast
Study: NCT01007994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: New Medication: Enalapril, Isradipine, Propranolol
Description: Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.~Dosing will be as follows:~ACEI: Enalapril \< 40 kg starting dose 2.5 mg titrate to 5 mg \> 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine \< 40 kg 2.5 mg \> 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol \<40 kg starting dose 10 mg titrate to 20 mg \>40 kg starting dose 20 mg titrate to 40 mg
Study: NCT03193021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiva Mid-Bore VVCS
Description: The device will be used to close all femoral venous access sites at the end of the case, which range from 3 - 4 access sites per patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Manual compression will be used to achieve hemostasis in all femoral venous access sites when the sheaths are pulled, which range from 3-4 access sites per patient.
Study: NCT04483921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute exercise
Description: Participants will complete a morning exercise bout at 70% of their individual maximal aerobic capacity to burn 200 kilocalories above their basal metabolic rate.
Study: NCT03665194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortexolone 17α-propionate solution
Description: Single topical application to be applied twice daily (0 hour and 12 hour) on Days 1-3 and Once Daily (0 hour) on Day 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT00744679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Participants continue to receive regularly-scheduled doses of Tysabri (300 mg infusion every 28±7 days) through the Tysabri Outreach: United Commitment to Health Prescribing Program (TOUCH) throughout the screening and assessment periods. Participants must continue to be dosed every 28±7 days in order to maintain steady-state pharmacokinetics.
Study: NCT02367872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272
Description: TAK-272 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272
Description: TAK-272 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272
Description: TAK-272 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-272
Description: TAK-272 tablet
Study: NCT03737994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Given IV
Study: NCT02787070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PQ supervised

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PQ unsupervised
Study: NCT01512290

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Theta Burst Transcranial Magnetic Stimulation
Description: This rTMS paradigm consists of 5 pulses at 50Hz repeated at 5Hz for 60 seconds with a total of 900 pulses per treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Theta Burst Transcranial Magnetic Stimulation
Description: This rTMS paradigm consists of 5 pulses at 50Hz repeated at 5Hz for 60 seconds with a total of 900 pulses per treatment
Study: NCT04401527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitrite
Description: Continuous intravenous infusion of Sodium Nitrite Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Continuous intravenous infusion of Normal Saline